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Identity 
Other names  
+13  
Trisomy 13 
Clinics and pathology 
Disease 
- Minimally differentiated acute myeloid leukemia 
(AML) (FAB Type M0) 
- Acute myeloblastic leukemia, without maturation 
(FAB Type M1) 
- Acute monoblastic/monocytic leukemia (FAB Type 
M5) 
- Acute erythroid leukemia (FAB Type M6) 
- B-cell acute lymphoblastic leukemia (B-ALL) 
- Myelodysplastic syndrome 
- Idiopathic myelofibrosis 
- Atypical chronic myeloid leukemia (CML) 
Epidemiology 
Trisomy 13 (when the sole cytogenetic abnormality) in 
AML manifests most commonly as minimally 
differentiated AML (FAB Type M0), and has a 
predilection for older men over 70.  
Mesa et al. found that the incidence rate of trisomy 13 
was 0.7% of all AML in their respective study. Other 
associated diseases have been, to date, described rarely.  
Trisomy 13 in acute myeloblastic leukemia, without 
maturation (FAB Type M1) has been described in two 
older men from India (Trivedi et al., 2009).  
Trisomy 13 in atypical CML was described in 1 case 
report from China in 2011 (Guo-Yu et al., 2011). 
Pathology 
According to Mehta et al. (1998), characteristic small 
hand-mirror blasts with cytoplasmic blebs and tails nd 
scanty small granules were seen in 13/24 cases and 
18/25 cases had small blasts would could easily be 
mistaken for lymphoblasts. Morphologic findings in 
bone marrow, according to Mesa et al. were: median of 
80% cellularity, 21% median bone marrow blasts 
(range 1%-94%), myelodysplastic changes in 56%, 
reticulin fibrosis in 11%, and ringed sideroblasts in 
11% of cases. 
Treatment 
One recent study (Fehniger et al., 2009) reported 
induction of sustained morphologic and cytogenetic 
complete remission in 2 older patients with AML with 
trisomy 13 (as the sole cytogenetic abnormality) treated 
with lenalidomide.  
However, in regards to a 2011 Fehniger article re: 
clinical trials of high-dose lenalidomide for older male 
AML patients, the Swedish AML group responded via 
an online published letter that lenalidomide has not
been shown to benefit older men with AML. 
Prognosis 
Trisomy 13 in AML is considered a poor prognostic 
factor, with low complete remission rate and brief 
remission duration.  
Per Mehta et al. (1998), median patient survival was 3 
months. The paper by Dohner et al. described 8 
individuals with trisomy 13 as the sole cytogenetic 
abnormality, with survival ranging from 0.5 to 14.7 
months.  
Mesa et al. report from a retrospective study a median 
survival of 6.1 months. 
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AML with trisomy 13 is strongly associated with 
presence of RUNX1 mutations and a high expression of 
FLT3 mRNA. Because FLT3 is localized on 
chromosome 13, Dicker et al. (2007) hypothesized that 
RUNX1 mutations may cooperate with trisomy 13 in 
leukemogenesis by increasing FLT3 transcript levels. 
They found that increasing FLT3 transcript levels 
revealed a highly significant (P < 0.001) ~5-fold 
increase in AML with RUNX1 mutations and trisomy 
13 compared with samples without trisomy 13. 
Cytogenetics 
Note 
Trisomy 13 occurs as a single clone in the majority of 
the cases so far reported. However, additional 
chromosome aberrations were observed in a second 
related clone. A few cases of tetrasomy 13 have been 
reported as second abnormal clone. 
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